Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin

Key Findings:  Resulting data suggests that the liquid oral use of CBDV (600mg) can modulate atypical striatal circuitry towards neurotypical function in this patient population.

Type of Study:  Double Blind Clinical Trial

Study Result:  Positive

Study Location(s):  Germany, Netherlands, Spain, United Kingdom

Year of Pub:  2021

Cannabinoids Studied:  Cannabinoid (unspecified), Cannabidivarin (CBDV)

Phytocannabinoid Source:  Unspecified

Dosage: 600 mg

Route of Administration:  Oral (Ingestion)

Link to study